IL6 and ovarian cancer: Improved OxPhos in ovarian cancer cells increase IL-6 production (307) which facilitates tumor cell survival and proliferation (308), changing efficacy to chemotherapy, and reduce progression-free survival of ovarian cancer patients (309).